Israeli biotech Butterfly Medical has received the CE Mark for its novel medical device for non-surgical treatment of Benign Prostate Hyperplasia (BPH) or enlarged prostate that affects 105 million men globally. The device is inserted in a 10-minute procedure under local anesthetic.

https://www.globes.co.il/en/article-butterfly-medical-awarded-ce-mark-for-prostate-device-1001213492